Reuters logo
BRIEF-Stemline Therapeutics reports oral presentation of sl-701 phase 2 data in second-line glioblastoma at the 21st annual meeting of the society of neuro-oncology (sno)
November 21, 2016 / 12:47 PM / a year ago

BRIEF-Stemline Therapeutics reports oral presentation of sl-701 phase 2 data in second-line glioblastoma at the 21st annual meeting of the society of neuro-oncology (sno)

Nov 21 (Reuters) - Stemline Therapeutics Inc :

* Stemline Therapeutics Inc- sl-701 was found to be safe and well-tolerated

* Stemline Therapeutics Inc- additional clinical data updates are expected next year

* Press release - Stemline Therapeutics announces oral presentation of sl-701 phase 2 data in second-line glioblastoma at the 21st annual meeting of the society of neuro-oncology (sno) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below